Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.

Safety of antiobesity drugs.

Cheung BM, Cheung TT, Samaranayake NR.

Ther Adv Drug Saf. 2013 Aug;4(4):171-81. doi: 10.1177/2042098613489721.

2.
3.

Rise and fall of anti-obesity drugs.

Li MF, Cheung BM.

World J Diabetes. 2011 Feb 15;2(2):19-23. doi: 10.4239/wjd.v2.i2.19.

4.

Tackling obesity: new therapeutic agents for assisted weight loss.

Karam J, McFarlane S.

Diabetes Metab Syndr Obes. 2010 Apr 26;3:95-112.

5.

Present and future: pharmacologic treatment of obesity.

Glandt M, Raz I.

J Obes. 2011;2011:636181. doi: 10.1155/2011/636181. Epub 2011 Feb 8.

6.

Weight considerations in pharmacotherapy for type 2 diabetes.

Cheng V, Kashyap SR.

J Obes. 2011;2011. pii: 984245. doi: 10.1155/2011/984245. Epub 2010 Sep 19.

7.

Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders.

Heal DJ, Gosden J, Smith SL.

Br J Clin Pharmacol. 2009 Dec;68(6):861-74. doi: 10.1111/j.1365-2125.2009.03549.x.

8.

The use of sibutramine in the management of obesity and related disorders: an update.

Tziomalos K, Krassas GE, Tzotzas T.

Vasc Health Risk Manag. 2009;5(1):441-52. Review.

9.

American College of Endocrinology Pre-Diabetes Consensus Conference: part two.

Bloomgarden ZT.

Diabetes Care. 2008 Nov;31(11):2222-9. doi: 10.2337/dc08-zb11. No abstract available.

10.

2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary].

Lau DC, Douketis JD, Morrison KM, Hramiak IM, Sharma AM, Ur E; Obesity Canada Clinical Practice Guidelines Expert Panel.

CMAJ. 2007 Apr 10;176(8):S1-13. Review. No abstract available.

Supplemental Content

Support Center